NCT00051116View on ClinicalTrials.gov

A Phase II Study of Continuous Versus Syncopated Dosing of CC-5013 for the Treatment of Refractory Multiple Myeloma

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

October 31, 2006

Study Completion Date

October 31, 2006

Conditions
Multiple Myeloma
Interventions
DRUG

CC-5013

Trial Locations (1)

72205

Myeloma Institute University of Arkansas for Medical Sciences, Little Rock

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY